Diagnosed w/PCa--Gleason 4+5 in R lobe, 1st/12 cores & 3+4 in L lobe 2nd/12 cores, biopsy & pathology by Johnathan Epstein, June 2018 (age 62).
Treatment: EBRT 81 Gy over 45 fractions (completed Jan 2019) + adjuvant Firmagon for 8 mos (completed Mar 2019). PSA reached undetectable nadir in Nov 2019.
PSA begins steady rise from nadir. Sept 2021 w/PSA @ 0.29 ng/ml, 3T Dotarem MRI --Negative. July 2022 w/ PSA @ 0.95, Pylarify PSMA scan shows intense focal uptake (SUV 20.2) in L apex of prostate only. 3T Dotarem MRI shows corresponding 0.9 cm lesion suspicious for tumor and diffusely decreased T2 signal intensity in prostate likely due to post radiation TX changes. Prostate size 17 cc. Continued monitoring only, was recommended unless PSA reaches 2 pts above nadir (the Astro-Phoenix criteria for BCR), per consults with Fox Chase & Sloan Kettering (Monmouth NJ), MED ONC & URO ONCs.
Feb 2023, PSA continues to rise to 2.21 ng/mL (exceeding the Astro-Phoenix criteria for BCR, a rise of 1.26 ng/mL over 6 months, with a declining PSADT of about 4.5 months). Mar 2023, second Pylarify PSMA shows that there is progressing malignancy within L lobe (much larger uptake area than before, now 18.3 x 22.3 mm, SUV now 25.5) and new uptake area (9.6 mm) in R lobe (SUV 5.6), but there continues to be no obvious evidence of regional lymphadenopathy. April 2023, recent PSA now 2.57, & Total Testosterone continues to drop below normal to 170 ng/dL.
Fox Chase MED ONC & RAD ONC both recommend Local Treatment, RAD ONC wants salvage HDR Brachy to entire prostate (no Focal), 24 Gy over two 12 Gy sessions and no adjuvant ADT. RAD ONC also wants biopsy for pathology (but with an irradiated prostate pathology may not be possible?) and SpaceOAR hydrogel to reduce RT complications?.
Local RAD ONC, partner of the RAD ONC who did my EBRT (since retired) disagrees, and does not recommend any salvage RT because I already received full dose EBRT and any further RT dramatically increases RT Toxicity risk in my case (I did have some mild RT side effects from initial EBRT) and added RT may not cure my PCa. Moreover, it is unclear if I have micro metastases, highly likely with Gleason 9 PCa, and that would render Local Treatment moot. He recommends ADT only and my Local MED ONC agrees (Orgovyx oral over Firmagon, intermittent ADT, to reduce side effects).
I am thinking of asking for another 3T Prostate MRI, this time w/o Dotarem (avoids bioaccumulation risk, had too many w/ Dotarem already) that can be used for fusion biopsy (vs random) and may shed some more light before I decide which way to proceed and if I go w/salvage Brachy, I think I may refuse biopsy (prostate needs time to heal from needles punctures and will delay RT?) and also refuse Space OAR (reduces the risk of insertion complications).
Any feedback/advice would be helpful and much appreciated.